FRANKFURT / LONDON (IT BOLTWISE) – The healthcare group Fresenius sees positive signals from the USA regarding a possible tariff exemption for generics and biosimilars. This development could have a significant impact on healthcare costs in the US, as generics make up a large proportion of prescribed medications. Michael Sen, CEO of Fresenius, emphasizes the importance of these drugs for controlling costs in the healthcare sector and sees the tariff decision as an opportunity to reduce dependence on imports.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
The healthcare group Fresenius is optimistic about the future regarding the potential tariff exemption for generics and biosimilars in the USA. These medications play a critical role in reducing healthcare costs because they account for a majority of medications prescribed but represent only a fraction of the total cost. Michael Sen, CEO of Fresenius, expressed confidence in the ongoing investigation under Section 232 of the U.S. trade laws in a conference call to discuss the company’s third-quarter results.
The investigation, initiated by the Trump administration, aims to assess the national security impact of U.S. reliance on pharmaceutical imports. Attention is paid not only to finished medicines, but also to the entire supply chain, including critical preliminary products such as active pharmaceutical ingredients. Sen emphasized that generics and biosimilars are key products to control healthcare costs. Given that generics make up about 85 percent of prescribed drugs in the U.S. but only account for 10 percent of the cost, a tariff would be counterproductive.
Biosimilars, which only make up 5 percent of prescribed drugs but cost 40 percent of the costs of prescribed drugs, could also benefit from the tariff exemption. The US administration has publicly signaled that these drug groups will likely be exempt from tariffs. This could not only reduce costs, but also improve security of supply in the United States, since many of these drugs are imported from abroad.
Fresenius sees itself in a systemically important position to address the shortage of essential medications in the USA. Sen emphasized that the US government should strive not to jeopardize security of supply through additional tariffs. The tariff decision could have far-reaching implications for the entire pharmaceutical industry, particularly in terms of drug pricing and availability. Developments in the USA could also serve as a signal to other markets on how to deal with dependence on pharmaceutical imports.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Fresenius sees opportunities for tariff exemption for generics in the USA”.